DZS Software enters partnership with Medidata

Medidata Solutions ($MDSO), a New York City-based provider of Web-based clinical trials software, is building up its network of technology partners. DZS Software Solutions of Bound Brook, NJ, said on April 6 that it has enhanced its clinical trial management system to automatically share trial data with Medidata's electronic data capture (EDC) and clinical trial management platform.

Basically, this arrangement enables life sciences companies that use Medidata software to feed data from clinical trials into DZS's software in an automated way--without the hassle reentering data from one system to the other. Nixing redundant data entry is one hedge against potentially costly errors in clinical trials. Also, DZS's efforts here are perhaps further proof that the clinical trials software community recognizes the growing influence of Medidata's EDC platform among healthcare product developers. Medidata, which has also recently added Logos Technologies to its roster of data-sharing partners, now has such partnerships with 12 software companies.

"Our partnership with Medidata Solutions positions DZS to take advantage of a leading EDC breakthrough solution that is quickly becoming a major force in the drug development arena," said Doron Steger, DZS Software's CEO, in a statement.

"We welcome DZS as a Medidata Technology Partner and are excited that our customers have the choice of leveraging DZS' easily configurable solution to streamline their trial management activities," said Glen de Vries, president of Medidata Solutions, in a statement. "DZS designed their solution for customers around the globe who are increasingly looking to efficiently use an advanced CTMS solution alongside Medidata Rave."

- find the DZS release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.